Skip to content

Trial · Interventional

CompletedPhase 4Results postedRegistry data

Effect of hCG on Receptivity of the Human Endometrium

NCTNCT01786252 (opens ClinicalTrials.gov in a new tab)Other idEndo-hCG-755Other idIRB 12-755F

Overview

Status
Completed
Phase
Phase 4
Enrollment
15 participants (actual)
Sponsor
Michigan State University · Other
Design
Not randomized · Open label (no masking)
Countries
1 country

United States

Start
Jan 2013
Primary completion
Mar 2016
Completion
Mar 2016
First posted
7 Feb 2013 (estimated)
Last update posted
24 Feb 2017
Conditions
Infertility · Subfertility

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20132014201520162017
  1. Ph 4

    Effect of hCG on Receptivity of the Human Endometrium

    NCT01786252

    Jan 2013 to Mar 2016

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Worldwide, 1 in 12 couples experience difficulty in getting pregnant and seek the help of assisted reproductive technologies (ART) such as in vitro fertilization (IVF-egg is fertilized by sperm outside the body), ovarian stimulation (medications are used to stimulate egg development) and intra-cytoplasmic injection (ICSI-single sperm is injected directly into the egg). Regardless of the ART procedure being performed, the newly fertilized embryo must still implant into the mothers endometrium (inner lining of uterus). This implantation process in humans is surprisingly inefficient and accounts for up to 50% of ART failures. Intrauterine infusion of hCG prior to embryo transfer has recently been shown to increase pregnancy rates but the cellular mechanism for this increase is unknown. Successful implantation requires the newly fertilized embryo and the endometrium develop in a synchronized manner. This coordinated development is accomplished, in part, by proteins secreted by the embryo which circulate throughout the maternal bloodstream and alert the maternal body organs (i.e. ovary, endometrium, breast, ect) that fertilization has occurred. One of the earliest of these secreted proteins is human chorionic gonadotropin (hCG), which is the molecule detected in over-the-counter pregnancy tests. From previous studies, we know that hCG production by the embryo alerts the ovary to continue producing progesterone, a hormone required for pregnancy. However, very little is known about the direct effect of hCG on the endometrium during early pregnancy in humans. Using animal models, hCG has been shown to induce specific changes in the endometrium, suggesting that embryo-derived hCG may be "priming" the endometrium in anticipation of implantation. The goal of this research study is to examine the direct effect of hCG on the human endometrium and see if this "priming effect" is also present in humans. Findings from this research may reveal whether pre-treatment with hCG can enhance ART outcomes, especially pregnancy rates.

Interventions

  • human chorionic gonadotropin (hCG)Drug
  • Placebo Comparator (for hCG)Drug

Arms2

  • Experimental

    Drug: human chorionic gonadotropin (hCG)

    Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media ("Global"-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis.

  • Placebo comparator

    IVF media ("Global"-trademark)

    Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.

Primary outcomes4

Outcomes the sponsor listed as primary.

  1. Endometrial Staging in hCG Versus Vehicle Treated Patients

    Time frame · 2 days following infusion of hCG or IVF media

    Registry description

    All H\&E-stained endometrial biopsies were analyzed in a blinded manner for endometrial dating and glandular and stromal development. Criteria for endometrial dating included the presence or absence of sub-nuclear vacuoles, which is one of the more reproducible features of the Noyes dating criteria. For the purposes of statistical analysis, the most advanced elements in each of the two endometrial compartments were considered. Data are specifically reported as days post-ovulation induction.

  2. Expression of hCG Target NOTCH1 Protein by IHC in Endometrial Glands

    Time frame · 2 days following infusion of hCG or IVF media

    Registry description

    Staining intensity of each section was quantified by image analysis software ImageJ (NIH) resulting in a Digital Histology Score (D-HSCORE), ranging from 0 to 255. Higher scores are associated with stronger staining/expression, while lower scores are the opposite.

  3. Expression of hCG Target NOTCH1 Protein by IHC in Endometrial Stroma

    Time frame · 2 days following infusion of hCG or IVF media

    Registry description

    Staining intensity of each section was quantified by image analysis software ImageJ (NIH) resulting in a Digital Histology Score (D-HSCORE), ranging from 0 to 255. Higher scores are associated with stronger staining/expression, while lower scores are the opposite.

  4. Expression of hCG Target C3 Protein by IHC in Endometrial Stroma

    Time frame · 2 days following infusion of hCG or IVF media

    Registry description

    Staining intensity of each section was quantified by image analysis software ImageJ (NIH) resulting in a Digital Histology Score (D-HSCORE), ranging from 0 to 255. Higher scores are associated with stronger staining/expression, while lower scores are the opposite.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeMean· 2 days following infusion of hCG or IVF media

Endometrial Staging in hCG Versus Vehicle Treated Patients

GroupValue (days)Spread
Drug: Human Chorionic Gonadotropin (hCG)4.00.577
IVF Media ("Global"-Trademark)4.60.56
Primary outcomeMean· 2 days following infusion of hCG or IVF media

Expression of hCG Target NOTCH1 Protein by IHC in Endometrial Glands

GroupValue (D-HSCORE)Spread
Drug: Human Chorionic Gonadotropin (hCG)111.917.0
IVF Media ("Global"-Trademark)84.5917.9
Primary outcomeMean· 2 days following infusion of hCG or IVF media

Expression of hCG Target NOTCH1 Protein by IHC in Endometrial Stroma

GroupValue (D-HSCORE)Spread
Drug: Human Chorionic Gonadotropin (hCG)85.6618.7
IVF Media ("Global"-Trademark)59.815.1
Primary outcomeMean· 2 days following infusion of hCG or IVF media

Expression of hCG Target C3 Protein by IHC in Endometrial Stroma

GroupValue (D-HSCORE)Spread
Drug: Human Chorionic Gonadotropin (hCG)85.311.6
IVF Media ("Global"-Trademark)59.821.6

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
IVF Media ("Global"-Trademark)Received IVF media infusion on Day 3 Post-Ovulation Induction–0 / 80 / 8
Drug: Human Chorionic Gonadotropin (hCG)Received hCG infusion on Day 3 Post-Ovulation Induction–0 / 70 / 7

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Other registry references

References listed at the registry that are not in PepBank. They link to PubMed.

  • DerivedStrug MR, Su R, Young JE, Dodds WG, Shavell VI, Diaz-Gimeno P, Ruiz-Alonso M, Simon C, Lessey BA, Leach RE, Fazleabas AT. Intrauterine human chorionic gonadotropin infusion in oocyte donors promotes endometrial synchrony and induction of early decidual markers for stromal survival: a randomized clinical trial. Hum Reprod. 2016 Jul;31(7):1552-61. doi: 10.1093/humrep/dew080. Epub 2016 Apr 26. PMID 27122490

Eligibility

Who could join, as posted.

Sex
Female
Age
from 18 Years up to 34 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: 1. between the ages of 18-34 years old 2. successfully applied for oocyte donor status at the Investigators Infertility clinic (The Fertility Center, 3230 Eagle Park Drive NE, suite 100. Grand Rapids MI 49525) 3. meet the ASRM criteria for oocyte donation Exclusion Criteria: 1. younger than 18 years old or older than 34 years old 2. have not successfully applied for oocyte donor status at the Investigators Infertility clinic (The Fertility Center, 3230 Eagle Park Drive NE, suite 100. Grand Rapids MI 49525) 3. do not meet the ASRM criteria for oocyte donation

PepBank is a research reference. Talk to a doctor before you use any peptide.